NEWS IN BRIEF

WuXi Biologics breaks ground on $240m manufacturing site near Beijing

By Flora Southey contact

- Last updated on GMT

WuXi Biologics' Biologics Center of Excellence (MFG8) in Shijiazhuan, China
WuXi Biologics' Biologics Center of Excellence (MFG8) in Shijiazhuan, China

Related tags: Wuxi biologics, China, CDMO

Construction has started at WuXi Biologics’ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to “develop and manufacture biologics more cost effectively”.

Contract development and manufacturing organisation (CDMO) WuXi Biologics announced last week it has broken ground on its Biologics Manufacturing Center of Excellence (MFG8) in Northern China’s Hebei province.

The $240m (€203m) facility will house process development labs, 5,000L bioreactor capacity for clinical manufacturing, and 48,000L bioreactor capacity for commercial manufacturing.

According to the firm, the plant will serve both Chinese and global clients, and be built to meet current good manufacturing practice (cGMP) standards of the US, the European Union, and China. Operations are expected to begin in 2020.

“We are pleased to break ground today and look forward to the operations of this new Biologics Center,” ​said Chris Chen in a statement.

“This facility will enable WuXi Biologics to develop and manufacture biologics more cost effectively as well as to provide a robust supply chain network for our global partners, and ultimately to benefit patients worldwide,” ​he added.

Related news

Show more

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Related suppliers

Follow us

Products

View more

Webinars